(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Cogent Biosciences, Inc.
Cogent Biosciences, Inc.
Blueprint Medicines Corporation
MacroGenics
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Centre Hospitalier Universitaire, Amiens
Fondazione IRCCS Policlinico San Matteo di Pavia
Cogent Biosciences, Inc.
M.D. Anderson Cancer Center
Blueprint Medicines Corporation
Uppsala University